News

Filter

Current filters:

Pharmaceuticaleltrombopag

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

16-06-2014

UK pharma major GlaxoSmithKline announced the results from the Phase III PETIT2 study evaluating the…

eltrombopagEuropeGlaxoSmithKlineHealth Medical PharmaHematologyItalyMajorMedicinePharmaceuticalResearchThrombocytopenic purpura

GSK’s eltrombopag performs well in Phase III PETIT2 study

GSK’s eltrombopag performs well in Phase III PETIT2 study

13-06-2014

UK pharma major GlaxoSmithKline has announced positive results from the Phase III PETIT2 study evaluating…

eltrombopagGlaxoSmithKlineOncologyPharmaceuticalResearchThrombocytopenic purpuraUK

Funding restrictions for rituximab and eltrombopag widened in New Zealand

Funding restrictions for rituximab and eltrombopag widened in New Zealand

20-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen…

Asia-PacificeltrombopagFinancialGlaxoSmithKlineHealthcareImmunologicalsNew ZealandPharmaceuticalrituximabRoche

COMPANY SPOTLIGHT

Menarini

Back to top